FI
PLX icon

Fosun International’s Protalix BioTherapeutics PLX Stock Holding History

Fosun International’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-263,140
Closed -$1.24M – 277
2019
Q2 		$1.24M Hold
263,140
– – 0.08% 143
2019
Q1 		$1.13M Hold
263,140
– – 0.07% 149
2018
Q4 		$795K Hold
263,140
– – 0.05% 166
2018
Q3 		$1.88M Buy
+263,140
New +$1.32M 0.09% 95

Other funds holding PLX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Fosun International's PLX Position: Q3 2019 in Review

Fosun International sold out of Protalix BioTherapeutics (PLX) in Q3 2019, closing a stake of 263,140 shares — an estimated $1.24M sold.

Fosun International first reported a position in PLX in Q3 2018 and held it in 4 quarters. The position peaked at $1.88M in Q3 2018. 31 funds tracked by Wall St. Rank hold PLX as of Q3 2019.

  • Fosun International reported no remaining Protalix BioTherapeutics position as of Q3 2019 after selling out during the quarter.
  • Fosun International sold 263,140 Protalix BioTherapeutics shares in Q3 2019, an estimated $1.24M.
  • Fosun International first reported a position in Protalix BioTherapeutics in Q3 2018 and held it in 4 quarters.
  • Fosun International's Protalix BioTherapeutics position peaked at $1.88M in Q3 2018.
  • 31 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2019.

Based on Fosun International's 13F filing for Q3 2019, filed 12 Nov 2019.